JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy

  NCT03937505

  Condition:   Ureter Injury
  Interventions:   Drug: IS-001;   Drug: No treatment
  Sponsor:   Intuitive Surgical
  Recruiting
• Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors

  NCT03144037

  Condition:   Breast Cancer
  Intervention:  
  Sponsor:   Texas Tech University Health Sciences Center, El Paso
  Recruiting
• Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis

  NCT03123809

  Condition:   Gastroparesis
  Intervention:   Device: Gastric Electrical Stimulation (GES) System
  Sponsor:   Texas Tech University Health Sciences Center, El Paso
  Recruiting
• Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

  NCT03188991

  Condition:   Pancreatic Mucinous-Cystic Neoplasm
  Intervention:   Drug: NanoPac®
  Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
  Recruiting
• Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

  NCT03077685

  Condition:   Locally Advanced Pancreatic Adenocarcinoma
  Intervention:   Drug: NanoPac®
  Sponsors:   NanOlogy, LLC;   US Biotest, Inc.
  Recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

  NCT03990363

  Condition:   Chronic Kidney Disease
  Interventions:   Drug: Verinurad;   Drug: Allopurinol;   Drug: Placebo for Verinurad;   Drug: Placebo for Allopurinol
  Sponsor:   AstraZeneca
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

  NCT03290508

  Condition:   Prostate Cancer
  Intervention:   Diagnostic Test: Prolaris Testing
  Sponsor:   Myriad Genetic Laboratories, Inc.
  Recruiting
• Buspirone for Early Satiety and Symptoms of Gastroparesis

  NCT03587142

  Condition:   Gastroparesis
  Interventions:   Drug: Buspirone;   Drug: Placebo
  Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

  NCT04124705

  Conditions:   Hypothyroidism;   Thyroid Disease;   Euthyroid;   Thyroid Gland;   Thyroid Hormones
  Interventions:   Drug: Armour® Thyroid;   Drug: Synthetic T4
  Sponsor:   Allergan
  Recruiting
• A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

  NCT04089735

  Condition:   Ocular Inflammation and Pain
  Interventions:   Drug: APP13007, 0.05%;   Drug: APP13007, 0.1%;   Drug: APP13007 Placebo, 0.05%;   Drug: APP13007 Placebo, 0.1%
  Sponsor:   Formosa Pharmaceuticals, Inc.
  Recruiting
• CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

  NCT04053543

  Condition:   PAH
  Intervention:   Drug: CXA-10
  Sponsors:   Complexa, Inc.;   Medpace, Inc.;   Innovative Analytics;   Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
  Recruiting
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Guselkumab;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

  NCT04026165

  Condition:   Diabetic Kidney Disease
  Interventions:   Drug: SEL;   Drug: Placebo
  Sponsor:   Gilead Sciences
  Recruiting
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

  NCT03943147

  Condition:   Lupus Nephritis
  Interventions:   Drug: BMS-986165;   Drug: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

  NCT03934736

  Condition:   End Stage Renal Disease on Dialysis (Diagnosis)
  Intervention:   Drug: HEPLISAV-B®
  Sponsor:   Dynavax Technologies Corporation
  Recruiting
• A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

  NCT03931785

  Condition:   Irritable Bowel Syndrome With Diarrhea (IBS-D)
  Interventions:   Drug: MD-7246;   Drug: Placebo
  Sponsors:   Ironwood Pharmaceuticals, Inc.;   Allergan Sales, LLC
  Recruiting
• A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

  NCT03891524

  Condition:   Arthroplasty, Replacement, Knee
  Interventions:   Drug: JNJ-70033093 25 mg;   Drug: JNJ-70033093 50 mg;   Drug: JNJ-70033093 100 mg;   Drug: JNJ-70033093 200 mg;   Drug: Placebo;   Drug: Enoxaparin 40 mg
  Sponsors:   Janssen Research & Development, LLC;   Bristol-Myers Squibb
  Recruiting
• Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

  NCT03888378

  Conditions:   Meibomian Gland Dysfunction;   MGD-Meibomian Gland Dysfunction
  Interventions:   Drug: 0.3% Topical Minocycline Ointment;   Drug: 1% Topical Minocycline Ointment;   Other: Topical Vehicle Ointment
  Sponsor:   Hovione Scientia Limited
  Recruiting
• Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

  NCT03874715

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Drug: Insulin Aspart SAR341402;   Drug: Insulin Aspart;   Drug: Insulin glargine U100
  Sponsor:   Sanofi
  Recruiting
• ViBone in Cervical and Lumbar Spine Fusion

  NCT03425682

  Conditions:   Spondylosis;   Cervical Spondylosis;   Spondylolisthesis;   Herniated Nucleus Pulposus;   Degenerative Disc Disease
  Intervention:   Other: ViBone
  Sponsor:   Aziyo Biologics, Inc.
  Recruiting
• A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa

  NCT03799627

  Conditions:   Anemia;   Dialysis-dependent Chronic Kidney Disease
  Interventions:   Drug: Vadadustat;   Drug: Epoetin Alfa;   Drug: Vadadustat TIW
  Sponsor:   Akebia Therapeutics
  Recruiting
• End-stage Renal Disease (ESRD) Pilot Study

  NCT03787368

  Condition:   Renal Dialysis
  Interventions:   Drug: BAY1213790;   Drug: 0.9% sodium chloride solution
  Sponsor:   Bayer
  Recruiting
• Diabetic Gastroparesis Study 05

  NCT03786380

  Condition:   Gastroparesis
  Intervention:   Drug: Relamorelin 10 μg
  Sponsor:   Allergan
  Recruiting
• Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

  NCT03766581

  Conditions:   Acute Ischemic Stroke;   Transient Ischemic Attack (TIA)
  Interventions:   Drug: BMS-986177;   Other: BMS-986177 Placebo;   Drug: Clopidogrel;   Drug: Aspirin
  Sponsors:   Bristol-Myers Squibb;   Janssen, LP
  Recruiting
• Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs

  NCT03733730

  Condition:   Cataract
  Interventions:   Device: ACRYSOF IQ RESTOR +3.0 D Toric IOL;   Device: ACRYSOF IQ RESTOR +2.5 D Toric IOL
  Sponsor:   Alcon Research
  Recruiting
• A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

  NCT03697109

  Condition:   Cushing Syndrome
  Interventions:   Drug: Relacorilant;   Other: Placebo
  Sponsor:   Corcept Therapeutics
  Recruiting
• GB001 in Adult Subjects With Moderate to Severe Asthma

  NCT03683576

  Condition:   Asthma
  Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
  Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
  Recruiting
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114

  Condition:   Relapsing Multiple Sclerosis
  Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Safety and Efficacy of KPI-121 in Subjects With DED

  NCT03616899

  Condition:   Kerato Conjunctivitis Sicca
  Interventions:   Drug: KPI-121 Ophthalmic Suspension;   Drug: Vehicle
  Sponsor:   Kala Pharmaceuticals, Inc.
  Recruiting
• Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

  NCT03598036

  Condition:   Focal Segmental Glomerulosclerosis
  Intervention:   Drug: Voclosporin
  Sponsor:   Aurinia Pharmaceuticals Inc.
  Recruiting
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110

  Condition:   Chronic Kidney Disease
  Interventions:   Drug: Empagliflozin;   Drug: Matching placebo
  Sponsors:   Boehringer Ingelheim;   Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead);   Eli Lilly and Company
  Recruiting
• Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

  NCT03561883

  Condition:   Gastroesophageal Reflux Disease (GERD)
  Interventions:   Drug: IW-3718;   Drug: placebo
  Sponsor:   Ironwood Pharmaceuticals, Inc.
  Recruiting
• A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

  NCT03544229

  Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
  Interventions:   Drug: TAK-906 Maleate;   Drug: TAK-906 Maleate Placebo
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD

  NCT03496623

  Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Inhaled treprostinil solution;   Drug: Placebo solution
  Sponsor:   United Therapeutics
  Recruiting
• PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

  NCT03449524

  Condition:   PAH
  Interventions:   Drug: 75mg CXA-10;   Drug: 150mg CXA-10;   Other: Placebo
  Sponsors:   Complexa, Inc.;   Medpace, Inc.;   Philips Healthcare;   Cardiovascular Clinical Science Foundation;   MicroConstants;   Innovative Analytics;   Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
  Recruiting
• Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02

  NCT03426345

  Conditions:   Gastroparesis;   Diabetes Mellitus
  Interventions:   Drug: Relamorelin;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03422510

  Condition:   Primary Focal Segmental Glomerulosclerosis
  Intervention:   Drug: CXA-10
  Sponsors:   Complexa, Inc.;   Kidney Research Network, formerly NephCure Accelerating Cures Institute;   Medpace, Inc.;   MicroConstants;   Arkana Labs;   NephCure Kidney International
  Recruiting
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197

  Condition:   mCRPC
  Interventions:   Drug: Talazoparib with enzalutamide;   Drug: Placebo with enzalutamide
  Sponsors:   Pfizer;   Astellas Pharma Inc
  Recruiting
• Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491

  Condition:   Pancreas Adenocarcinoma
  Interventions:   Device: NovoTTF-100L(P);   Drug: Gemcitabine;   Drug: nab paclitaxel
  Sponsor:   NovoCure Ltd.
  Recruiting
• Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

  NCT03315143

  Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
  Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
  Sponsor:   Sanofi
  Recruiting
• Palbociclib in Real World Practice

  NCT03280303

  Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
  Intervention:   Other: non-interventional
  Sponsor:   Pfizer
  Recruiting
• An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)

  NCT03173092

  Condition:   Multiple Myeloma
  Interventions:   Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Recruiting
• Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

  NCT03068130

  Condition:   Pulmonary Hypertension
  Intervention:   Drug: Bardoxolone methyl
  Sponsor:   Reata Pharmaceuticals, Inc.
  Recruiting
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

  NCT03022825

  Condition:   Bladder Cancer
  Interventions:   Drug: ALT-803;   Drug: BCG
  Sponsor:   Altor BioScience
  Recruiting
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT02998528

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Biological: Nivolumab;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ipilimumab
  Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
  Recruiting
• TARGET Post-Approval Study

  NCT02800863

  Condition:   Complex Regional Pain Syndrome (CRPS)
  Intervention:   Device: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)
  Sponsor:   Abbott Medical Devices
  Recruiting
• The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

  NCT02675114

  Condition:   Aortic Stenosis
  Interventions:   Procedure: Surgical aortic valve replacement (SAVR);   Device: Transcatheter Aortic Valve Replacement (TAVR)
  Sponsor:   Edwards Lifesciences
  Recruiting
• A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

  NCT02636946

  Conditions:   Glaucoma;   Open-Angle Ocular Hypertension
  Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
  Sponsor:   Allergan
  Recruiting
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

  NCT02630316

  Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
  Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
  Sponsor:   United Therapeutics
  Recruiting
• CLUSTER Trial for Outbreak Detection and Response

  NCT04053075

  Condition:   Cluster Detection
  Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
  Recruiting
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

  NCT03691649

  Condition:   Glaucoma and Ocular Hypertension
  Interventions:   Drug: DE-117 Ophthalmic Solution;   Drug: Timolol Maleate Ophthalmic Solution 0.5%
  Sponsor:   Santen Inc.
  Recruiting
• A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

  NCT03661866

  Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
  Intervention:  
  Sponsor:   Target PharmaSolutions, Inc.
  Recruiting
• Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

  NCT03595124

  Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Axitinib;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

  NCT03580356

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

  NCT03493685

  Condition:   Focal Segmental Glomerulosclerosis
  Interventions:   Drug: sparsentan;   Drug: irbesartan
  Sponsor:   Retrophin, Inc.
  Recruiting
• A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

  NCT03093480

  Condition:   Hemophilia A With Inhibitors
  Intervention:   Biological: rFVIIIFc
  Sponsors:   Bioverativ Therapeutics Inc.;   Swedish Orphan Biovitrum
  Recruiting
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507

  Condition:   Cancer Survivor
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Registry for Patients With Chronic Hypoparathyroidism

  NCT01922440

  Condition:   Chronic Hypoparathyroidism
  Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
  Sponsor:   Shire
  Recruiting